ZURICH (MarketWatch) -- Roche Holding AG RHHBY expects to soon launch anemia drug Mircera globally for use in chronic kidney disease, said Dan Kemmler, commercial director for the treatment ...

We were unable to process your request ... Increases in pegylated epoetin beta (Mircera) and darbepoetin (Aranesp) use. For over two decades, epoetin alfa has been the most commonly prescribed ...

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring U.S. sales of the anemia med, claiming that Mircera doesn't infringe on Amgen's ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically ...

Here's the action so far: A court ruled that Roche's anemia drug Mircera infringes on Amgen's patents on Epogen. But though Young granted Amgen's request for a temporary injunction against Roche's ...

ZURICH (MarketWatch) -- Roche Holding AG RHHBY plans to launch anemia drug Mircera immediately in the U.K. and Germany and is confident it will win U.S. approval for the drug later this year ...

Rumors about a test for Mircera started circulating when cyclist ... New forms of doping arise all the time, but the formal lab accreditation process is relatively slow (the method at issue ...

(CN) - The Federal Circuit refused to lift an injunction barring F. Hoffman-La Roche Ltd. from importing its anemia treatment, Mircera, to the United States, saying the drug infringes on some of Amgen ...

Amgen Inc. said a federal court granted the biotechnology company a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., while also upholding a ...

Mircera is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. It is formulated as a sterile, preservative-free ...

The FDA delayed an approval decision on Roche’s Mircera pending a fall advisory committee review, spelling temporary relief for marketers of similar biologics.Mircera, an experimental treatment for ...